Ftse Mib
34.507,84
0,68%
DAX
18.575,94
0,86%
S&P 500
5.354,03
1,18%
NASDAQ
17.187,90
1,96%
Bitcoin
71.168,41
0,13%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroSense Therapeutics Ltd (NRSN) NeuroSense Therapeutics Ltd (NRSN) Notizie

NRSN

NeuroSense Therapeutics (NRSN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRSN
DataOraFonteTitoloSimboloCompagnia
20/05/202415:00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/05/202415:05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/05/202414:45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202415:19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202414:30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202414:30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202414:30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
11/04/202401:16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/04/202414:30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/04/202415:29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/02/202414:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
21/02/202414:30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202419:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/02/202415:27PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202414:45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323:00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202315:24PR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202314:00PR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202322:01PR Newswire (US)NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202312:17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/11/202314:45PR Newswire (US)NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/11/202315:20PR Newswire (US)NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/11/202315:00PR Newswire (US)NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS ConferencesNASDAQ:NRSNNeuroSense Therapeutics Ltd
06/11/202314:30PR Newswire (US)NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/11/202314:00PR Newswire (US)NeuroSense Therapeutics to Participate in BIO-Europe FallNASDAQ:NRSNNeuroSense Therapeutics Ltd
17/10/202314:30PR Newswire (US)NeuroSense CEO Provides Q3 2023 UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/10/202315:10PR Newswire (US)NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/09/202315:05PR Newswire (US)European Medicines Agency Grants NeuroSense SME StatusNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRSN

La tua Cronologia

EU
BNPGC
BNP Paribas 1% 17apr2024
BMF
OC1F37
OC1F37 - Janeiro 2037
BIT
P1UKK7
NLBNPIT1UKK7 20991231 14...
USOTC
PGFY
Pingify (CE)
ASX
BHPLOY
TG
M1L
Maple Leaf Foods
LSE
UC44
Ubsetf Wsrgba
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network